Company Filing History:
Years Active: 2019-2023
Title: Innovations of Jianhong Chu in Cancer Immunotherapy
Introduction
Jianhong Chu is a prominent inventor based in Columbus, OH (US). He has made significant contributions to the field of cancer immunotherapy, particularly in the development of chimeric antigen receptors (CAR) for treating multiple myeloma. With a total of 3 patents, his work is paving the way for new therapeutic strategies in oncology.
Latest Patents
One of Jianhong Chu's latest patents focuses on CS1-specific chimeric antigen receptor engineered immune effector cells. This patent discloses chimeric antigen receptors that can specifically recognize tumor-associated antigens (TAA) on multiple myeloma (MM) cells. Additionally, it describes immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. The methods outlined in this patent provide a novel approach to delivering anti-tumor immunity in subjects with MM through the adoptive transfer of these engineered immune effector cells.
Career Highlights
Jianhong Chu is associated with the Ohio State Innovation Foundation, where he continues to advance research in cancer treatment. His innovative work has garnered attention in the scientific community, contributing to the understanding and potential treatment of multiple myeloma.
Collaborations
Jianhong collaborates with notable colleagues, including Jianhua Yu and Craig Hofmeister. Their combined expertise enhances the research efforts at the Ohio State Innovation Foundation.
Conclusion
Jianhong Chu's contributions to cancer immunotherapy through his innovative patents are significant. His work not only advances scientific knowledge but also holds promise for improving treatment options for patients with multiple myeloma.